📰 Adapted News
Page 5 - Adapted News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Adapted. Real-time updates on events, politics, business and more.
October 18, 2022
Resurrecting billon-year-old enzymes reveals how photosynthesis adapted to the rise of oxygen.
October 17, 2022
Star Indian all-rounder Hardik Pandya said on Monday that he wants to be exceptional in his fielding skills and his goal for the remainder of the year is to tak
October 13, 2022
Sera collected from participants 7 days after administration of a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine showed a substantial increase in the Omicron BA.4/BA.5 neutralizing
October 13, 2022
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) Thursday announced positive early data from the Phase 2/3 study of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster
October 12, 2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of their Omicron
September 26, 2022
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Monday that they have completed a submission to the U.S. Food and Drug Administration requesting Emergency Use Authorization
September 13, 2022
ATHENS, Sept. 12 (Xinhua) -- Vaccines adapted to fighting the latest Omicron variants of COVID-19 are now available in Greece, it was announced on Monday. The t
September 12, 2022
CHMP recommendation based on favorable data from Omicron-adapted vaccines The Omicron BA.4/BA.5 bivalent COVID-19 booster vaccine combines 15-ug of mRNA encoding the wild-type spike protein
September 1, 2022
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced a 30 µg booster dose of their Omicron BA.1- Bivalent COVID-19 Vaccine, COMIRNATY Original, has been recommended for
September 1, 2022
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine The Omicron BA.1-adapted bivalent COVID-19 vaccine